The amyloid cascade hypothesis, which posits that amyloid-β accumulation is the key event in Alzheimer disease neurodegeneration, has dominated the field for 20 years. Recent findings, however, show that neuronalinjury biomarkers are independent of amyloid-β, calling for reconsideration of the pathological cascade and assessment of alternative therapeutic strategies.
The path to this conclusion began a few years ago in the context of lively enthusiasm for Aβ imaging as a tool for early diagnosis of AD, and as a method to ultimately prove or disprove the Aβ cascade hypothesis. In 2010, Clifford Jack and colleagues from the Mayo Clinic proposed a model, largely based on the amyloid cascade hypothesis, that integrated the most thoroughly validated biomarkers of AD pathology. 2 This model described the typical progression of the disease in which Aβ biomarkers become abnormal first, followed by biomarkers of neurodegeneration that precede cognitive symptoms.
One year later, the National Institute on Aging-Alzheimer's Association published recommendations on the definition of preclinical AD for research purposes. 3 On the basis of the conceptual model of Jack et al., 2 three sequential stages of preclinical AD were proposed: stage 1 (amyloidosis), in which only biomarkers of Aβ processes are found; stage 2, in which both Aβ bio markers and biomarkers of neuronal injury are present; and stage 3, when subtle co gnitive impairment is evident. 3 In June 2012, these criteria were operationalized and applied to a populationbased sample of 450 cognitively normal elderly individuals. 4 In this cohort, 43% had no abnormal biomarker profiles (stage 0), and 31% of the individuals were within stages 1 to 3 (that is, they were considered to have entered the AD pathway, and would, therefore, progress to AD). 23% of the sample, however, had neuronal injury without evidence of Aβ deposition, which did not follow the sequence of the model. Rather than being categorized as a stage of preclinical AD, these individuals were grouped under the distinct, biologically defined category of SNAP. Scientific support for this interpretation was fervently awaited.
Such support was expected from a parallel publication from the same group, which reported the short-term clinical outcomes for each stage of pathology. 5 The re searchers found that conversion to mild cognitive impairment (MCI) or dementia increased across most stages of pathology, but the results were inconclusive with regard to the SNAP group, probably owing to the short follow-up and modest number of individuals who converted to MCI or dementia (none converted to AD). Of those with SNAP, 10% converted within 1 year-a conversion rate not markedly different to that seen in patients with preclinical AD stage 0 (5%), stage 1 (12%) or stages 1-3 combined (18%). Nevertheless, the SNAP group remained classified as non-AD. Now, results from the most recent study have led to reconsideration of this interpretation. 1 The investigators compared the SNAP group to those with preclinical AD stages 1-3 on various measures. As the most frequent non-AD pathophysiological processes are cerebrovascular disease and α-synucleinopathy, the SNAP group was expected to differ from the preclinical AD group on these parameters. However, the two groups were indistinguishable on any measures of cerebrovascular risk factors or α-synucleinopathy, and the authors concluded that the initial appearance of braininjury biomarkers in cognitively normal people may not depend on Aβ amyloidosis.
This conclusion has major implications for AD research and treatment. It contradicts not only earlier statements that SNAP represents non-AD pathology and that Aβ Arguments against the new findings include the fact that Aβ imaging mainly measures only fibrillar Aβ and not the more toxic soluble form. Consequently, 'negative' imaging might not rule out the presence of toxic Aβ; this outcome is unlikely, however, as the two forms are thought to be in equilib rium in AD. Issues related to methodo logy, such as reliance on the sensitivity of imaging techniques and the definition of criteria for thresholds and regions of interest, raise additional concern. Nevertheless, the fact that neuronal injury can, at least partly, occur independently of Aβ-related processes, can no longer be ignored.
Further evidence to support Aβ-indepen dent pathology in AD has begun to accumulate. Studies have shown Aβ-independent neuronal injury in apoliprotein-E4 car riers 6 and, in a study of carriers of mutations linked to early-onset AD, neuronal injury was evident before or at the same time as Aβ deposition. 7, 8 We are entering an era in which the unitary view of AD as a disease with a single sequential pathological pathwaywith Aβ considered as the only initial and causal event-is likely to be progressively replaced by a more complex picture in which AD is considered as a multiparameter pathology that is subtended by several partly indepen dent pathological processes. Regional discrepancies in the degree of atrophy, hypometabolism 9 and amyloid deposition 10 in the AD brain support the conclusions that, in this disease, neuronal injury could be caused by different factors, with various possible sequences of pathological events (Figure 1 ). For example, Aβ, tau and possibly other pathologies may be partly independent of one another, each under the influence of both independent and common risk factors, and able to interact with each other, thereby promoting the AD neuropathological cascade. Indeed, evidence exists to suggest that Aβ promotes tau toxicity and vice versa.
According to this new view, one might consider all CSF and neuroimaging biomarkers (along with the presence of subtle cognitive deficits and even subjective cognitive decline) to the same degree, with the additive presence of each factor causing an incremental increase in the risk of AD patho physiology and of progression to AD. Even brain atrophy and hypo metabolism could be considered as partly independent processes that contribute to this risk. 9 Cog nitive impairment is thought to occur follow ing structural brain alterations, but in some cases can be evident before detectable changes in the brain. The timing of cognitive impairment will depend on interindividual variability, cognitive reserve and compensation processes and, thus, consideration of cognitive impairment separately (instead of sequentially), as for other bi omarkers of AD, might be preferable.
In conclusion, the proposal of SNAP has been a short-lived but useful concept as it led to the hypothesis that AD-related neuronal injury is independent of Aβ. Future research should reveal whether this view is true and whether it will dominate the field. What is certain is that this claim will provoke lively debate in the AD research community. 
